8-K: Jupiter Neurosciences Secures $20M Flexible Financing

Jupiter Neurosciences, Inc. has entered into agreements with Yorkville Advisors Global, LP for up to $20 million in financing to fund its Parkinson's trial and Nugevia product line.

Summary

• Secured up to $20.0 million in flexible financing from YA II PN, LTD. (Yorkville) through a Standby Equity Purchase Agreement (SEPA) and Convertible Promissory Notes.
• Received an initial $3.72 million pre-paid advance on October 27, 2025, in exchange for a $4.0 million convertible promissory note, issued with a 7.0% original issue discount.
• An additional $1.86 million pre-paid advance is anticipated for a $2.0 million convertible note, contingent on registration statement effectiveness and stockholder approval for share issuances exceeding the Exchange Cap.
• The convertible notes bear an annual interest rate of 8%, increasing to 18% upon an Event of Default, and mature on October 24, 2026.
• Monthly repayments on the notes commence 75 days after October 24, 2025, and include 1/10th of the outstanding principal, a 5% payment premium, and accrued interest, payable in cash or through equity sales under the SEPA.
• The SEPA provides the option to sell up to an additional $14.0 million in common stock to Yorkville at a 3.0% discount to the lowest daily volume-weighted average price (VWAP) during a three-day pricing period.
• Proceeds from SEPA advances must first be used to repay the outstanding convertible notes.
• Issued 131,909 commitment shares to Yorkville, valued at $200,000, and paid a $25,000 cash structuring fee.
• Engaged Revere Securities LLC as a finder, with compensation including 8.0% of pre-paid advance proceeds and $18,000 per month for 12 months, payable upon raising $5.0 million or more in additional financing.

Sentiment

Score: 6

Explanation: The financing provides essential capital for Jupiter Neurosciences' critical Phase 2 trial and product launch, which is a positive step for a clinical-stage company. However, the terms, including the original issue discount, high interest rates (especially on default), and potential for significant shareholder dilution, introduce considerable financial costs and risks. The need for shareholder approval for full utilization of the SEPA also adds a layer of uncertainty. Overall, it's a necessary but costly and potentially dilutive financing.

Positives

• Secured up to $20.0 million in capital, providing crucial funding for ongoing operations and strategic initiatives.
• An initial $3.72 million advance provides immediate liquidity.
• Financing is intended to support the Phase 2 trial of JOTROL for Parkinson's Disease, a key therapeutic pipeline asset.
• Funds will accelerate direct-to-consumer marketing and sales growth of the Nugevia nutritional product line.
• The SEPA offers flexible, at-the-market equity financing at the company's discretion, without mandatory minimums or non-usage fees.
• Yorkville is restricted from short selling or hedging transactions that establish a net short position in common stock during the agreement term.

Negatives

• Convertible promissory notes were issued with a 7.0% original issue discount, reducing the net proceeds received by the company.
• The annual interest rate on the notes is 8%, increasing to 18% upon an Event of Default, representing a significant cost of capital.
• Repayment of the notes includes a 5% payment premium, adding to the cost unless repaid via SEPA advances.
• Sales of common stock under the SEPA will occur at a 3.0% discount to the market price, leading to dilution for existing shareholders.
• Significant potential for shareholder dilution due to the conversion features of the notes and the equity sales under the SEPA, especially if the stock price declines.
• The company is restricted from entering into "Variable Rate Transactions" with other parties until the promissory notes are fully repaid, limiting future financing flexibility.
• Restrictions on related party payments, including executive/employee loans and accrued salaries, until notes are repaid, with limited exceptions for bonuses.
• Finder's fees to Revere Securities LLC include 8.0% of pre-paid advance proceeds and $18,000 per month for 12 months, adding to the cost of financing.

Risks

• Dilution Risk: Significant potential for dilution to existing shareholders from the conversion of promissory notes and sales of common stock under the SEPA, especially if the stock price decreases.
• Stockholder Approval Risk: The ability to issue shares in excess of the 19.99% Exchange Cap (7,180,504 shares) is contingent on obtaining requisite stockholder approval at the upcoming 2025 Annual Stockholders Meeting. Failure to obtain this approval would severely limit the company's ability to utilize the full $20.0 million commitment.
• Market Price Volatility: The purchase price for shares under the SEPA is tied to the lowest daily VWAP, and the default conversion price for notes is tied to 95% of the lowest daily VWAP, making the company susceptible to market price fluctuations and potentially leading to more shares being issued for the same capital.
• Event of Default Risk: Various events, including failure to make timely payments, bankruptcy, significant judgments, or delisting, could trigger an Event of Default, increasing the interest rate to 18% and allowing the holder to accelerate repayment or convert at a more favorable (for the holder) default conversion price.
• Registration Statement Effectiveness Risk: The second tranche of the pre-paid advance and the ability to draw under the SEPA are contingent on the effectiveness of a registration statement, which could be delayed by SEC review or other factors.
• Liquidity Risk: While providing capital, the financing structure involves ongoing obligations (monthly payments, interest) that require continued liquidity or further equity sales.
• Operational Risks: The success of the Phase 2 Parkinson's trial and Nugevia product growth are subject to clinical, regulatory, and market risks inherent in the biopharmaceutical and consumer health industries.

Future Outlook

The company intends to use the financing proceeds primarily to support the Phase 2 trial of its lead asset, JOTROL, for Parkinson's Disease, and to accelerate direct-to-consumer marketing and sales growth of its recently launched nutritional product line, Nugevia. Remaining funds will be allocated to working capital and other general corporate purposes.

Management Comments

• "We believe this financing will provide us with the capital required to complete the Phase II Parkinsons Disease trial and continue to support the launch of our DTC longevity nutraceutical, Nugevia."
• "We are grateful for Yorkvilles support at this critical stage of our Companys growth and look forward to executing on both our projects and business strategy."

Industry Context

This financing arrangement is typical for a clinical-stage biopharmaceutical company like Jupiter Neurosciences, which requires substantial capital to fund costly drug development (e.g., Phase 2 trials) and commercialization efforts (e.g., Nugevia product launch). The dual-path strategy of pursuing CNS therapeutics and expanding into consumer longevity markets is a common approach to diversify revenue streams and mitigate the high risks associated with drug development. Equity lines and convertible notes provide flexible access to capital, albeit often at dilutive terms, which is a common trade-off for companies without significant recurring revenue or late-stage assets.

Comparison to Industry Standards

• The 7% original issue discount and 8% annual interest rate (18% default) on convertible notes are within the range seen for high-risk, early-stage biotech financing, though on the higher side, reflecting the company's stage and perceived risk.
• The 3% discount to VWAP for SEPA advances is a standard mechanism for at-the-market equity facilities, providing liquidity but also ensuring market-based pricing.
• The 19.99% Exchange Cap is a common Nasdaq listing rule limitation, requiring shareholder approval for larger dilutive issuances, which is a standard governance practice.
• Restrictions on "Variable Rate Transactions" and related party payments are typical covenants in such financing agreements to protect the investor's position and ensure funds are used for core business operations.
• The finder's fees, including a percentage of proceeds and monthly payments, are customary for securing such complex financing arrangements, though the total cost should be carefully evaluated against industry benchmarks for similar-sized deals.

Related Party Transactions

• The company is restricted from repaying any loans to executives or employees or making payments on related party debt (including outstanding and accrued salaries) until the promissory notes are fully repaid.
• An exception allows for the payment of one-half of 2022-2024 outstanding bonuses to executives after the first pre-paid advance closing, and the other half after the second pre-paid advance closing.

Stakeholder Impact

• Shareholders: Face significant potential dilution from the conversion of notes and sales of common stock under the SEPA. The stock price could be negatively impacted by the issuance of new shares at a discount.
• Employees/Executives: Restricted from receiving repayment of loans or certain accrued salaries until the promissory notes are fully repaid, with a specific allowance for 2022-2024 bonuses in two tranches.
• Creditors (Yorkville): Gains a strong position as a lender and potential equity holder, with protective covenants, high default interest, and anti-dilution provisions.
• Customers (Nugevia): Potential benefit from accelerated marketing and sales growth of the Nugevia product line due to increased funding.
• Patients (Parkinson's Trial): Potential benefit from the continued funding of the Phase 2 JOTROL trial, which could lead to a new therapeutic option.

Next Steps

• File a registration statement for the resale of shares under the SEPA within 30 calendar days after October 24, 2025.
• Seek requisite stockholder approval at the 2025 Annual Stockholders Meeting on December 19, 2025, to issue shares in excess of the Exchange Cap.
• Receive the second $1.86 million pre-paid advance after the registration statement becomes effective and stockholder approval is obtained.
• Commence monthly repayments on the convertible notes 75 days after October 24, 2025.
• Continue to advance the Phase 2 trial of JOTROL for Parkinson's Disease.
• Accelerate direct-to-consumer marketing and sales growth of the Nugevia product line.

Key Dates

Recommendation

While securing up to $20 million in financing is a critical and positive development for a clinical-stage biopharmaceutical company like Jupiter Neurosciences, enabling it to fund its Phase 2 Parkinson's trial and Nugevia product launch, the terms of the financing introduce significant risks and costs. The 7% original issue discount, 8% annual interest (18% on default), 5% payment premium, and 3% discount on SEPA equity sales are relatively expensive. The potential for substantial shareholder dilution, especially if the stock price declines, and the need for shareholder approval to fully utilize the SEPA, create considerable uncertainty. Investors should 'hold' to monitor the company's progress in its clinical trials and Nugevia sales, as well as the outcome of the shareholder vote, before making further investment decisions. The financing provides a lifeline but comes with a high price tag and dilutive implications.

Keywords

Jupiter Neurosciences, JUNS, YA II PN LTD, Yorkville Advisors, Standby Equity Purchase Agreement, SEPA, Convertible Promissory Note, Financing, Equity Line, Dilution, Parkinson's Disease, JOTROL, Nugevia, Biopharmaceutical, Clinical Stage, Neurosciences, SEC Filing, 8-K, Capital Raise, Stockholder Approval, Nasdaq